| __timestamp | GSK plc | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8246000000 | 7751000 |
| Thursday, January 1, 2015 | 9232000000 | 10251000 |
| Friday, January 1, 2016 | 9366000000 | 9575000 |
| Sunday, January 1, 2017 | 9672000000 | 10912000 |
| Monday, January 1, 2018 | 9915000000 | 11049000 |
| Tuesday, January 1, 2019 | 11402000000 | 11646000 |
| Wednesday, January 1, 2020 | 11456000000 | 13265000 |
| Friday, January 1, 2021 | 10975000000 | 25805000 |
| Saturday, January 1, 2022 | 8372000000 | 35182000 |
| Sunday, January 1, 2023 | 9385000000 | 94999000 |
Unlocking the unknown
In the world of pharmaceuticals, understanding the financial health of a company is crucial. This chart provides a fascinating comparison of Selling, General, and Administrative (SG&A) expenses between GSK plc and Viridian Therapeutics, Inc. from 2014 to 2023. GSK, a global healthcare giant, consistently reported SG&A expenses in the billions, peaking at approximately $11.4 billion in 2019. In contrast, Viridian, a smaller biotech firm, saw its expenses grow from around $7.8 million in 2014 to nearly $95 million in 2023, marking a staggering increase of over 1,100%. This dramatic rise reflects Viridian's aggressive expansion and investment in its operations. Meanwhile, GSK's expenses showed a more stable trend, with a slight dip in 2022. This data highlights the contrasting financial strategies of a well-established pharmaceutical leader and an emerging biotech player.
Cost Management Insights: SG&A Expenses for Novartis AG and Viridian Therapeutics, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Viridian Therapeutics, Inc.
Comparing SG&A Expenses: GSK plc vs Exelixis, Inc. Trends and Insights
GSK plc vs Axsome Therapeutics, Inc.: SG&A Expense Trends
GSK plc or Corcept Therapeutics Incorporated: Who Manages SG&A Costs Better?
Research and Development Expenses Breakdown: GSK plc vs Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Viridian Therapeutics, Inc.
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Viridian Therapeutics, Inc.
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Soleno Therapeutics, Inc. or Viridian Therapeutics, Inc.